The protective efficacy of a DNA vaccine against hepatitis E virus (HEV) infection was tested in cynomolgus macaques (cynos) vaccinated with a plasmid containing a full-length HEV open-reading frame 2 (ORF2) sequence (Burmese strain) and subsequently challenged with a heterologous strain of HEV (Mexican strain). Cynos administered vaccine by gene gun developed antibodies to HEV (anti-HEV), whereas cynos administered vaccine by intradermal injections and cynos administered a mock DNA construct did not develop anti-HEV. Anti-HEV-positive cynos were protected from HEV infection after challenge with an inoculum that produced infection in the anti-HEV-negative cynos. These results indicate that DNA vaccine with HEV ORF2 administered by gene gun is protective against a heterologous viral challenge.
economic loss in several developing countries make the disease a public health problem and have thus intensified the search for an effective vaccine.
HEV, a nonenveloped virus, has a positive-strand RNA genome of ∼7.2 kb spanning a coding region that includes 3 open-reading frames (ORFs). ORF1 encodes nonstructural proteins, ORF2 encodes the capsid protein, and ORF3 encodes a cytoskeleton-associated phosphoprotein of undefined function [7, 8] . Despite the identification of at least 4 HEV genotypes worldwide [9] , there appears to be a single HEV serotype, which should facilitate the development of a vaccine [10, 11] . However, failure to propagate HEV in cell culture has precluded any effort to produce a killed or live-attenuated vaccine, and all attempts have focused on recombinant proteins of the major structural protein (encoded by ORF2) expressed in bacteria or eukaroytic systems [12] [13] [14] [15] [16] . Prototype recombinant vaccines, based on either full-length or truncated ORF2 protein, have generated high-titer antibody responses [12] [13] [14] [15] [16] . Protection against hepatitis, but not against HEV infection, was reported in most of these studies [12] [13] [14] [15] ; however, full protection in some animals was reported in one study [16] . Recently, a preclinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine in cynomolgus macaques (cynos) reported full protection in some cynos vaccinated with only 1 or 2 doses of the vaccine [17] .
Vaccination with DNA has been shown to result in the synthesis of immunizing viral proteins within host cells and the induction of humoral and cellular immune responses. Vaccination of animals with plasmid DNA has produced effective immune responses against several viruses, including influenza virus, rabies virus, HIV, hepatitis B virus (HBV), hepatitis C virus, and herpes simplex virus [18] . Vaccination with DNA with an HEV ORF2 construct was shown to elicit antibody to HEV (anti-HEV) in mice [19, 20] . Intramuscular injection of plasmid DNA encoding HEV ORF2 induced a modest humoral immune response in cynos; 50% of the cynos were protected against infection when challenged with a heterologous HEV strain [21] . In the present study, we sought to improve the efficacy of our candidate DNA vaccine by administering it with a gene gun.
MATERIALS AND METHODS
Plasmid construct. Production of a full-length HEV ORF2 (based on the Burmese HEV strain sequence) pcDNA3-based plasmid has been described elsewhere [21] . The vector, designated "pcHEVORF2," possesses a eukaryotic promoter derived from human cytomegalovirus, a polyadenylation signal, and a Kozak sequence (an ACC sequence preceding the AUG start codon) [22] . The construct was amplified in Escherichia coli, and endotoxin-free plasmid DNA preparations were purified by use of anion exchange chromatography (Giga Endotoxin-Free Purification kit; Qiagen). Concentration and purity of the plasmid DNA were determined by absorbance spectroscopy and by gel electrophoresis. Plasmid DNA resuspended at a concentration of 1.0 mg/mL (in endotoxin-free Tris-EDTA buffer) was stored at -70ЊC.
Preparation of DNA gold microcarriers. Gold beads were coated with plasmid DNA by adding 50 mg of 1.6-mm gold powder (BioRad) and 1.0 mg/mL plasmid DNA to a 1.5-mL microcentrifuge tube containing 100 mL of 0.05 mol/L Spermidine (Sigma Chemical). Plasmid DNA and gold beads were coprecipitated by the addition of 100 mL of 1.0 mol/L CaCl 2 during vortex mixing, and the precipitate was allowed to settle for 10 min at room temperature, was washed 3 times with absolute ethanol, and was resuspended in ethanol solution containing 0.05 mg/mL polyvinylpyrrolidone. The suspension was coated on the inside of Tefzel tubing (BioRad) that was cut into 0.5-inch cartridges and was used in a Helios gene-gun system (BioRad).
DNA vaccination and viral challenge of cynos. Seven anti-HEV-negative female cynos (2.5-5.0 kg) were used for these experiments. Three cynos in the gene-gun group (Cy9801, Cy9805, and Cy9807) and 2 in the intradermal-injection group (Cy9808 and Cy9811) received pcHEVORF2 DNA. Two cynos (Cy9813 and Cy9814) were vaccinated by gene gun with a mock vector (pcDNA3.1). A 25-mg dose of the vaccine was delivered to multiple sites on the shaved abdomen of the cynos by gene gun, at a helium pressure of 28,124 g/cm 2 . Cynos vaccinated via intradermal injection received an identical amount of DNA (25 mg) suspended in 0.1 mol/L PBS (pH 7.5). All cynos received 3 additional vaccine doses (25 mg each), which were identical to the primary vaccine dose, at 4-week intervals. Three weeks after the last vaccine dose, all cynos were challenged intravenously with 1.0 mL of a 10% wt/vol human stool suspension, diluted 1:100 in 0.1 mol/L PBS, that contained 10,000 cyno infectious doses (CyIDs) of the Mexican strain of HEV (Mexico no. 14) [12, 13, 15] . Serum specimens were obtained twice weekly before and during the vaccination period and after viral challenge and were stored at -70ЊC until tested. Stool samples were obtained daily for ∼15 weeks after viral challenge and were stored at -70ЊC until tested. Alanine aminotransferase (ALT) levels were measured in fresh serum specimens by use of a colorimetric method on a Prochem-V clinical analyzer (Drew Scientific). Individual cutoff values ( SD) for ALT mean + 3 levels were established for each cyno by use of at least 10 prevaccination measurements.
Detection of HEV RNA in feces or serum was considered to be evidence of HEV infection. An elevation in ALT level above the cutoff value, as established for each cyno in 2 consecutive serum specimens, was considered to be biochemical evidence of hepatitis. The housing, maintenance, and care of the cynos complied with all relevant guidelines and requirements of the Animal Care and Use Committee of the Centers for Disease Control and Prevention.
Serologic testing. All serum specimens were tested for anti-HEV by use of an EIA, as described elsewhere [23] . In brief, polystyrene microtiter plate wells (Immunolon II; Dynatech Laboratories) were coated with 100 mL of affinity-purified glutathione-S-transferase-HEV mosaic fusion protein at a concentration of 5 mg/mL in 0.1 mol/L PBS (pH 7.5) overnight at room temperature. Serum samples were diluted 1:20 in dilution buffer containing 0.1 mol/L PBS (pH 7.5), 0.1% Tween 20, and 10% normal goat serum. Antibody binding was determined by use of affinity-purified anti-human IgG conjugated to horseradish peroxidase (Pierce). Absorbance was measured at 490 nm in an automated plate reader (Dynex Technologies). Cutoff values for anti-HEV reactivity were established for each cyno by use of the mean of 10 prevaccination samples plus 0.200. End-point titers were determined by serial 2-fold dilutions of the specimens in the dilution buffer.
Anti-HEV titers were also determined, by use of the same EIA format, in archived specimens obtained from cynos (Cy8901 and Cy8902) vaccinated with 3 doses of recombinant tryptophan synthetase E (trpE)-HEV fusion protein in a previous study [12] . These specimens (obtained on day 91 after vaccination) had been tested earlier by use of a Western-blot assay using an HEV ORF2 antigen [12] .
Detection of HEV RNA. Stool and serum specimens were tested for HEV RNA by use of nested reverse-transcriptase (RT) polymerase chain reaction (PCR). RNA was extracted from 100 mL of serum or 10% stool suspension in 0.1% PBS (pH 6.8) by use of commercial silica-gel microspin columns (QIAmp Viral Isolation kit; Qiagen), as recommended by the manufacturer. The extracted RNA (50 mL) was subjected to RT-PCR in the presence of an outer set of primers, followed by a second round of nested PCR using an inner set of primers. The sequences of the primers are as follows: SK-EU1 (outer sense; 5 -GTT GTC TCA GCC AAT GGC GAG CC-3 ), SK-EU2 (inner sense; 5 -TGG AGA ATG CTC AGC AGG ATA A-3 ), SK-EU3 (inner antisense; 5 -TAA GTG GAC TGG TCG TAC TCG GC-3 ), and SK-EU4 (outer antisense; 5 -GCC TGC GCG CCG GTC GCA ACA-3 ). The cycling profile for both rounds of PCR was 1 cycle at 94ЊC for 2 min, 29 cycles at 94ЊC for 45 s, 62ЊC for 20 s, 72ЊC for 1 min, and 1 cycle at 72ЊC for 7 min. All PCR products were analyzed on a 2% agarose/1ϫ Tris-borate EDTA gel with a sample load of 5 mL, were subjected to electrophoresis for 30 min at 100 V, and were stained with ethidium bromide.
RESULTS
All 3 cynos administered the pcHEVORF2 vaccine by gene gun developed a humoral immune response, with an increase in anti-HEV titers after each booster dose (figure 1). Cy9801 developed an anti-HEV titer of 1:640 after the first vaccination, which increased to 1:1280 after the final booster dose. Antibody titers in cynos Cy9805 and Cy9807 increased from 1:80 after the first vaccination to 1:320 after the final vaccination dose. The geometric mean anti-HEV titers in these cynos after each vaccine dose are shown in table 1. All 3 cynos in this group had a similar pattern, consisting of an increase followed by a gradual decrease in the anti-HEV levels, after each vaccine dose. Anti-HEV was not detected in any of the serum samples obtained during the entire vaccination period from the 2 cynos vaccinated intradermally with pcHEVORF2 (Cy9808 and Cy9811) or the 2 control cynos vaccinated with a mock vector (Cy9813 and Cy9814) (figure 1).
After the gene gun-vaccinated cynos had been challenged with 10,000 CyIDs of the HEV inoculum, HEV RNA was not detected in any stool or serum samples. In addition, there was no increase in anti-HEV levels, and anti-HEV levels decreased throughout the period following the HEV challenge (figure 2 and table 2). ALT levels remained below the cutoff value in 2 cynos (Cy9801 and Cy9807) and were elevated in Cy9805 on days 55, 62, 65, and 69. These elevations in ALT levels did not seem to be associated with HEV infection, because they occurred well after the 4-6 week incubation period generally observed in experimental HEV infection [7] and because no markers of infection were detected.
In the group vaccinated intradermally, HEV RNA was excreted in stools during days 4-40 (Cy9808) and days 4-32 (Cy9811) after challenge. HEV RNA was detected in serum during days 6-30 (Cy9808) and days 6-15 (Cy9811) after challenge (table  2) . Both of these cynos seroconverted to anti-HEV during days 21-35 after challenge, with anti-HEV titers reaching 1:320 on day 104 after challenge (figure 2). Neither cyno had elevated ALT levels. The 2 control cynos vaccinated with the mock vector (Cy9813 and Cy9814) excreted HEV RNA in their stools during days 2-28 and days 6-22 after challenge, respectively. HEV RNA was detected in serum during days 9-19 (Cy9813) and days 15-36 (Cy9814) after challenge (table 2) . Seroconversion to anti-HEV in these 2 cynos was detected during days 21-28, with anti-HEV titers reaching 1:320 at the end of the challenge period. One of the cynos in this group (Cy9813) had a significant elevation in ALT level on days 6 and 9 (figure 2). The absence of elevated ALT levels in Cy9814 may indicate a subclinical infection in this cyno. Anti-HEV titers in archived specimens obtained from cynos vaccinated with a recombinant trpE-HEV fusion protein [12] were 1:81,920 (Cy8901) and 1:640 (Cy8902), as determined by the EIA used in the present study.
DISCUSSION
DNA vaccines have been shown to induce both humoral and cellular immune responses and to elicit protective immunity in several animal models of infectious disease, such as those for HBV and HIV infection, as well as in humans [24] [25] [26] [27] [28] . Induction of immune responses against specific pathogens with plasmid DNA vaccination has been accomplished by use of epidermal, intradermal, mucosal, intramuscular, and intravenous routes of administration. Although the mechanism of DNA vaccination is not completely understood, the dose and route of vaccination have been shown to markedly affect the type and magnitude of immune response. The most efficient vaccinations with an influenza virus hemagglutinin gene were achieved by using a gene gun to deliver DNA-coated gold beads to the skin [29] . The results reported in the present study demonstrate the effectiveness of a gene gun-delivered HEV ORF2 DNA vaccine in inducing an efficacious humoral immune response against HEV infection in cynos. Anti-HEV was detected in cynos that had received DNA epidermally by gene gun, whereas no anti-HEV was detected in cynos vaccinated intradermally with the same amount of DNA. In our previous study of intramuscular vaccination with HEV ORF2 DNA, a DNA dose 4 times greater than that used in the present study induced lower anti-HEV levels than those observed in the present study, and only 50% of the vaccinated cynos were protected after challenge with HEV [21] .
In the present study, there was a clear correlation between the presence of anti-HEV and protection against HEV challenge. These results strongly suggest that anti-HEV provides a marker of overall immunity against HEV and are consistent with the results of previous studies of HEV ORF2 vaccinations conducted with macaques [12] [13] [14] [15] [16] [17] 30] . The sterile immunity in gene gun-vaccinated cynos, as evidenced by the absence of viremia, virus shedding in stools, or a boosting effect on antibody response, could be related to neutralization of the challenge virus by antibodies circulating at levels that prevented adsorption of the virus to target cell receptors [31] or to other mechanisms that are not fully understood for HEV. The gradual decrease in vaccine-induced anti-HEV levels observed in the present study has been reported in previous vaccine-related studies of hepatitis E [11, 16] .
The anti-HEV titers, determined by the same EIA, observed in the cynos vaccinated with HEV ORF2 DNA by gene gun in the present study are lower than the anti-HEV titers induced in cynos vaccinated with HEV ORF2 recombinant proteins reported in a previous study [12] . Despite the presence of high anti-HEV titers induced by HEV ORF2 recombinant proteins, full protection against a heterologous viral challenge was not achieved, because the vaccinated cynos shed HEV in stools. Although the protective efficacy may be related to the infectious dose of the challenge inocula, it is conceivable that there are differences in the affinity and/or avidity of antibodies induced by DNA and those by recombinant protein vaccinations. It has been shown that differences in survival of mice vaccinated with 2 hemagglutinin DNA vaccines, which induced similar antibody titers, were the result of differences in the avidity maturation of the antibodies in the 2 groups of mice [32] .
Vaccination by gene gun bombards cells with DNA-coated gold microparticles; this delivery system overcomes membrane barriers and enables direct delivery of DNA into skin cells, including Langerhans cells, which are potent antigen-presenting cells [33] . It has been suggested that the physical insult of goldparticle bombardment may promote the release of cytokines and chemokines during inflammatory reactions [34] . This "adjuvant effect" may be a significant factor that makes vaccination by gene gun superior to other vaccination methods, as documented in studies that compared various methods of immunogen administration [35] [36] [37] [38] . In the present study, gene-gun delivery of an HEV ORF2 DNA vaccine construct that did not contain any molecular adjuvant, cytokine, or other immunostimulatory sequences induced a humoral immune response efficacious enough to confer complete protection against the heterologous HEV challenge. In the present study, none of the cynos vaccinated by intradermal injection showed detectable levels of anti-HEV. Failure to develop an antibody response after intradermal vaccination with DNA has been noted elsewhere [39, 40] . Similar to our results, the advantage of vaccination by gene gun was also reported in a study of rabies DNA vaccine in which intradermal injection of the vaccine failed to elicit an antibody response in cynos, but delivery by gene gun induced a strong immune response [41] .
In conclusion, the results of the present study demonstrate that DNA vaccination with a plasmid encoding full-length HEV ORF2 delivered by gene gun is an effective means of inducing cross-protective immunity against HEV infection in cynos. Genetic vaccination apparently allows efficient processing, expression, and presentation of HEV structural protein and the generation of an immune response sufficient to confer complete protection against HEV infection.
